KAMILA JULIA KROL

PhD Student

PhD program:: XXXVII
email: kamiliajulia.krol@uniroma1.it
phone: +390668592652
building: Ospedale Pediatrico Bambino Gesù, Viale di S. Paolo 15, 00146 Rome, Italy




supervisor: Doriana Fruci
co-supervisor: Raffaele Strippoli

Research: In vivo anti-tumour safety and efficacy of NK cell-based immunotherapeutic approach in preclinical models

EDUCATION:
Master of Science, major in Molecular biotechnology (Jagiellonian Univeristy, Faculty of Biology | 2018 - 2021)

Bachelor Pedagogical studies for Biology teachers in Primary School (Jagiellonian Univeristy, Faculty of Biology | 2016 - 2019)

Bachelor of Science, major in Biology (Jagiellonian Univeristy, Faculty of Biology | 2015 - 2018)

WORK EXPERIENCE:
Research trainee | SEPT 2020- JUL 2021 (Biolab program administrated by Fulbright commission; Oklahoma Medical Research Foundation, Oklahoma City, OK, USA)

Master student | OCT 2018- JUN 2021 (Jagiellonian University, Faculty of Biochemistry, Biophysics and Biotechnology; Department of Cell Biology)

Bachelor student | OCT 2015- SEP 2018 (Faculty of Biology, Department of Genetics and Evolutionism)

PAPERS:
CO-AUTHOR 2023
Two bullets in the gun: combining immunotherapy with chemotherapy to defeat neuroblastoma by targeting adrenergic-mesenchymal plasticity; doi: 10.3389/fimmu.2023.1268645

CO-AUTHOR 2021
Bioactive compounds from Lactarius deterrimus interfere with the invasive potential of gastric cancer cells; doi: 10.18388/abp.2020_5915

CO-AUTHOR 2021
Distal Lck Promoter-Driven Cre Shows Cell Type-Specific Function in Innate-like T Cells; doi: 10.4049/immunohorizons.2100079

CO-FIRST AUTHOR 2020
Epidermal Growth Factor (EGF) Augments the Invasive Potential of Human Glioblastoma Multiforme Cells via the Activation of Collaborative EGFR/ROS-Dependent Signaling; doi: 10.3390/ijms21103605

SCHOLARSHIPS:
CAPSTONE-ETN/ Marie Skłodowska-Curie Action/ Horizon2020 PhD scholarship winner (ESR10) (2021-2024)

Chancellor's Scholarship for the best students (2019-2020)
Winner of the student project 2019
“Epidermal growth factor (EGF) promotes cytoskeletal rearrangements and augments invasive potential via Cx43/ROS dependent manner within human T98G glioblastoma multiforme cells in vitro"

Research products

11573/1724624 - 2024 - Combining ERAP1 silencing and entinostat therapy to overcome resistance to cancer immunotherapy in neuroblastoma
Tempora, P.; D'amico, S.; Gragera, P.; Damiani, V.; Krol, K.; Scaldaferri, V.; Pandey, K.; Chung, S.; Lucarini, V.; Giorda, E.; Scarsella, M.; Volpe, G.; Pezzullo, M.; De Stefanis, C.; D'oria, V.; De Angelis, L.; Giovannoni, R.; De Ioris, M. A.; Melaiu, O.; Purcell, A. W.; Locatelli, F.; Fruci, D. - 01a Articolo in rivista
paper: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (London : BioMed Central) pp. 1-18 - issn: 1756-9966 - wos: WOS:001340314400001 (0) - scopus: 2-s2.0-85207170943 (0)

11573/1690017 - 2023 - Two bullets in the gun: combining immunotherapy with chemotherapy to defeat neuroblastoma by targeting adrenergic-mesenchymal plasticity
D’Amico, Silvia; Tempora, Patrizia; Gragera, Paula; Król, Kamila; Melaiu, Ombretta; De Ioris, Maria Antonietta; Locatelli, Franco; Fruci, Doriana - 01g Articolo di rassegna (Review)
paper: FRONTIERS IN IMMUNOLOGY (Lausanne : Frontiers Research Foundation, 2010-) pp. 1-8 - issn: 1664-3224 - wos: WOS:001082251100001 (1) - scopus: 2-s2.0-85174300302 (1)

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma